A case of 17-beta-hydroxysteroid dehydrogenase deficiency type 3 in adult endocrinologist practice

17β-Hydroxysteroid dehydrogenase 3 deficiency (17HSD3) is a rare autosomal recessive cause of 46, XY disorders of sex development resulting from HSD17B3 gene mutations, in which conversion of androstenedione to testosterone is impared. The clinical signs of 17HSD3 deficiency depend on the residual activity of the enzyme. The diagnosis of 17HSD3 deficiency is based on reduced testosterone/androstenedione ratio (T/AD < 0.8). Patients are usually assigned at birth and raise as female. If the diagnosis is made before puberty, gonadectomy is recommended, taking into account the risk of masculinization during the puberty and estrogen therapy initiation in this period. If the diagnosis of 17HSD3 deficiency is established during puberty, when virilization manifests, the therapeutic strategy is based on the results of comprehensive psychological testing and gender identity of a patient. In patients with more pronounced masculinization or diagnosis established shortly after birth, who are assigned at birth and raise as male, testosterone therapy is used to achieve a male phenotype. The 17HSD3 deficiency and virilization often result in a change of gender identity during puberty. The article presents a clinical case of 17-βhydroxysteroid dehydrogenase type 3 deficiency with late diagnosis due to parental will. The diagnostic approaches and management of the disease are also described.

1. Kolodkina AA, Kalinchenko NYu, Nizhnik AN, et al. Clinical, hormonal, and molecular-genetic characteristics of two cases of abnormal sex formation (ASF) in 46XY subjects caused by type 3 17-beta hydroxysteroid dehydrogenase deficiency. Problems of Endocrinology-2011-T. 3.- S. 25-30.(In Russ.).

2. Kalinchenko NYu, Tyul’pakov AN. Novaya klassifikaciya zabolevanij, svyazannyh s narusheniem formirovaniya pola. Obsuzhdenie mezhdunarodnogo konsensusa po peresmotru terminologii i klassifikacii germafroditizma. Vestnik reproduktivnogo zdorov’ya. 2008;(12):49-51. (In Russ.).

3. Yang Z, Ye L, Wang W, et al. 17β-Hydroxysteroid dehydrogenase 3 deficiency: Three case reports and a systematic review. J Steroid Biochem Mol Biol. 2017;(174):141-145. doi: https://doi.org/10.1016/j.jsbmb.2017.08.012

4. Mendonca BB, Gomes NL, Costa EM, et al. 46,XY disorder of sex development (DSD) due to 17β-hydroxysteroid dehydrogenase type 3 deficiency. J Steroid Biochem Mol Biol. 2017;165(Pt A):79-85. doi: https://doi.org/10.1016/j.jsbmb.2016.05.002

5. Gonçalves CI, Carriço J, Bastos M, Lemos MC. Disorder of sex development due to 17-beta-hydroxysteroid dehydrogenase type 3 deficiency: A case report and review of 70 different HSD17B3 mutations reported in 239 patients. Int J Mol Sci. 2022;23(17):10026. doi: https://doi.org/10.3390/ijms231710026

6. Geissler WM, Davis DL, Wu L, et al. Male pseudohermaphroditism caused by mutations of testicular 17 beta-hydroxysteroid dehydrogenase 3. Nat. Genet. 1994;7(1):34-39. doi: https://doi.org/10.1038/ng0594-34

7. Luu V.The Analysis and characteristics of multiple types of human 17 beta-hydroxysteroid dehydrogenase. J. Steroid Biochem. Mol. Biol. 2001;76(1-5): 143-151. doi: https://doi.org/10.1016/s0960-0760(00)00155-2

8. Boehmer ALM, Brinkmann AO, Sandkuijl LA, et al. 17β-Hydroxysteroid Dehydrogenase-3 Deficiency: Diagnosis, Phenotypic Variability, Population Genetics, and Worldwide Distribution of Ancient and de Novo Mutations1. J Clin Endocrinol Metab. 1999;84(12):4713-4721. doi: https://doi.org/10.1210/jcem.84.12.6174

9. Faisal Ahmed S, Iqbal A, Hughes IA. The testosterone:androstenedione ratio in male undermasculinization. Clin Endocrinol (Oxf). 2000;53(6):697-702. doi: https://doi.org/10.1046/j.1365-2265.2000.01166.x

10. George MM, New MI, Ten S, et al. The clinical and molecular heterogeneity of 17betaHSD-3 enzyme deficiency. Horm Res Paediatr. 2010;74(4): 229-240. doi: https://doi.org/10.1159/000318004

11. Rosler A, Silverstein S, Abeliovich D. A (R80Q) mutation in 17 beta-hydroxysteroid dehydrogenase type 3 gene among Arabs of Israel is associated with pseudohermaphroditism in males and normal asymptomatic females. J. Clin.Endocrinol. Metab. 1996;81(5):1827-1831. doi: https://doi.org/10.1210/jcem.81.5.8626842

12. Ben Rhouma B, Kallabi F, Mahfoudh N, et al. Novel cases of Tunisian patients with mutations in the gene encoding 17β-hydroxysteroid dehydrogenase type 3 and a founder effect. J Steroid Biochem Mol Biol. 2017;(165):86-94. doi: https://doi.org/10.1016/j.jsbmb.2016.03.007

13. Chuang J, Vallerie A, Breech L, et al. Complexities of gender assignment in 17β-hydroxysteroid dehydrogenase type 3 deficiency: is there a role for early orchiectomy? Int J Pediatr Endocrinol. 2013;2013(1):15. doi: https://doi.org/10.1186/1687-9856-2013-15

14. Lee Y.S., Kirk J.M., Stanhope R.G., et al. Phenotypic variability in 17beta-hydroxysteroid dehydrogenase-3 deficiency and diagnostic pitfalls. Clin Endocrinol (Oxf.) 2007;67(1):20-28. doi: https://doi.org/10.1111/j.1365-2265.2007.02829.x

15. Mendonca BB, Inacio M, Arnhold IJ, et al. Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase 3 deficiency. Diagnosis, psychological evaluation, and managemen. Medicine. 2000;79(5):299-309. doi: https://doi.org/10.1097/00005792-200009000-00003

16. Park D, Lee PA, Witchel SF. Progressive Virilization of a Pubertal Phenotypic Female: 17β-Hydroxysteroid Dehydrogenase Deficiency. J Pediatr Adolesc Gynecol. 1996;9(1):9-11. doi: https://doi.org/10.1016/S1083-3188(96)70003-7